Literature DB >> 27214684

Aerosolized ribavirin: the most expensive drug for pneumonia.

R F Chemaly1, S L Aitken2, C R Wolfe3, R Jain4, M J Boeckh5,6.   

Abstract

Dramatic, overnight cost increases of important orphan and generic medications have recently come under public and government scrutiny. We highlight the case of aerosolized ribavirin, an important antiviral agent in hematopoietic stem cell transplantation which, because of substantial price increases, may now cost more than the transplant procedure itself.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  average wholesale price; cost; hematologic malignancy; hematopoietic stem cell transplantation; pediatrics; respiratory syncytial virus

Mesh：

Substances：

Year:  2016        PMID： 27214684     DOI： 10.1111/tid.12551

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN： 1398-2273            Impact factor:   2.228


  17 in total

1.  Parainfluenza Virus 3-Specific T Cells: Opportunity for Intervention?

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

2.  Refinement of estimates of mortality risk using the Radiologic Severity Index in hematologic malignancy patients with respiratory syncytial virus infection.

Authors:  Ajay Sheshadri; Mahtab Karimipour; Erik Vakil; Lara Bashoura; Myrna Godoy; Muhammad H Arain; Scott E Evans; Burton F Dickey; David E Ost; Roy F Chemaly; Saadia A Faiz
Journal:  Transpl Infect Dis       Date:  2019-05-28       Impact factor: 2.228

Review 3.  Severe Respiratory Viral Infections: New Evidence and Changing Paradigms.

Authors:  James M Walter; Richard G Wunderink
Journal:  Infect Dis Clin North Am       Date:  2017-07-05       Impact factor: 5.982

Review 4.  Airway disease in hematologic malignancies.

Authors:  Ricardo J José; Burton F Dickey; Ajay Sheshadri
Journal:  Expert Rev Respir Med       Date:  2022-02-21       Impact factor: 4.300

5.  The Use of Aerosolized Ribavirin in Respiratory Syncytial Virus Lower Respiratory Tract Infections in Adult Immunocompromised Patients: A Systematic Review.

Authors:  Lisa Avery; Charles Hoffmann; Karen M Whalen
Journal:  Hosp Pharm       Date:  2019-03-27

6.  Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies.

Authors:  Erik Vakil; Ajay Sheshadri; Saadia A Faiz; Dimpy P Shah; Yayuan Zhu; Liang Li; Joumana Kmeid; Jacques Azzi; Amulya Balagani; Lara Bashoura; Ella Ariza-Heredia; Roy F Chemaly
Journal:  Transpl Infect Dis       Date:  2018-09-21       Impact factor: 2.228

Review 7.  Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies.

Authors:  Fareed Khawaja; Roy F Chemaly
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

Review 8.  Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.

Authors:  Lauren Fontana; Lynne Strasfeld
Journal:  Infect Dis Clin North Am       Date:  2019-03-30       Impact factor: 5.982

9.  A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract.

Authors:  Francisco M Marty; Roy F Chemaly; Kathleen M Mullane; Dong-Gun Lee; Hans H Hirsch; Catherine B Small; Anne Bergeron; Shmuel Shoham; Per Ljungman; Alpana Waghmare; Elodie Blanchard; Yae-Jean Kim; Matt McKevitt; Danielle P Porter; Robert Jordan; Ying Guo; Polina German; Michael Boeckh; Timothy R Watkins; Jason W Chien; Sanjeet S Dadwal
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

10.  Supplemental Oxygen-Free Days in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus.

Authors:  Alpana Waghmare; Hu Xie; Louise Kimball; Jessica Yi; Sezen Özkök; Wendy Leisenring; Guang-Shing Cheng; Janet A Englund; Timothy R Watkins; Jason W Chien; Michael Boeckh
Journal:  J Infect Dis       Date:  2017-12-05       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.